Page 'Sub' Navigation:
Page Path 'Breadcrumb':
Management Team
Barry D. Quart, PharmD
President, Chief Executive Officer and Director
Dr. Quart was elected as a director and appointed as our President and CEO in December, 2006. From 2002 until December, 2006, Dr. Quart was President of Napo Pharmaceuticals, Inc., where he was instrumental in bringing the company public on the London Stock Exchange in July 2006. Prior to Napo, Dr. Quart was Senior Vice President, Pfizer Global Research and Development and the Director of Pfizer's La Jolla Laboratories, where he was responsible for approximately 1,000 employees and an annual budget of almost $300 million. Prior to Pfizer's acquisition of the Warner-Lambert Company, Dr. Quart was President of Research and Development at Agouron Pharmaceuticals, Inc., a division of the Warner-Lambert Company, since 1999. Dr. Quart had joined Agouron in 1993 and was instrumental in the development and registration of nelfinavir (Viracept®), which went from the lab bench to NDA approval in 38 months. Dr. Quart spent over ten years at Bristol-Myers Squibb in both Clinical Research and Regulatory Affairs prior to Agouron and was actively involved in the development and registration of important drugs for the treatment of HIV and cancer, including paclitaxel (Taxol®), didanosine (Videx®), and stavudine (Zerit®). He has a PharmD from University of California, San Francisco.[top]
Stephen R. Davis, JD
Executive Vice President, Chief Operating Officer
Mr. Davis was appointed as our Executive Vice President and Chief Operating Officer in April 2010. Prior to joining Ardea, Mr. Davis served as President and Chief Executive Officer of Neurogen Corporation, which was acquired by Ligand Pharmaceuticals in December 2009. Prior to becoming CEO in February 2008, Mr. Davis served as Neurogen's Chief Operating Officer beginning in April 2005 and Executive Vice President and Chief Business Officer from September 2001 through April 2005. Mr. Davis was also a member of the Board of Directors of Neurogen. Mr. Davis joined Neurogen in 1994 as Vice President of Finance and Chief Financial Officer. While at Neurogen, Mr. Davis completed numerous collaborations with global pharmaceutical companies. From 1990 through June 1994, Mr. Davis practiced as a corporate and securities attorney with Milbank, Tweed, Hadley & McCloy LLP in New York City. Previously, Mr. Davis practiced as a Certified Public Accountant with Arthur Andersen & Co. Mr. Davis received his BS in Accounting from Southern Nazarene University and his JD from Vanderbilt University.[top]
John W. Beck
Senior Vice President, Finance and Operations and Chief Financial Officer
Mr. Beck was appointed as our Senior Vice President, Finance and Operations and Chief Financial Officer in May 2008 bringing more than 19 years of financial management experience to the Company. He was previously one of the founders of Metabasis Therapeutics, Inc. where he most recently served as their Senior Vice President of Finance, Treasurer and Chief Financial Officer. Prior to co-founding Metabasis, he served as Director of Finance at Neurocrine Biosciences, Inc. and played an important role in Neurocrine's initial public offering. Mr. Beck previously held financial management positions at high technology and financial services companies including General Dynamics and Ernst and Young LLP. Mr. Beck received a BA in accounting from the University of Washington and also holds a ThB in theology from a Seattle, Washington-based seminary. Mr. Beck is a licensed certified public accountant (inactive status) in the state of California and is a member of the American Institute of Certified Public Accountants and the Association of Bioscience Financial Officers.[top]
Christopher W. Krueger, JD, MBA
Senior Vice President, Chief Business Officer
Mr. Krueger was appointed as our Senior Vice President and Chief Business Officer in March, 2007. Mr. Krueger was previously Senior Vice President, Business Development and Strategic Alliances at Protemix Corporation during 2006, Senior Vice President, Business Development at Xencor, Inc. from 2004 to 2006, Senior Vice President, Chief Business Officer at X-Ceptor Therapeutics, Inc. (now Exelixis, Inc.) from 2002 to 2004 and Vice President, Business Development and Strategic Alliances and General Counsel at Aurora Biosciences Corporation (now Vertex Pharmaceuticals, Inc.) from 2000 to 2002. His responsibilities at these drug development companies included licensing, strategic alliances, mergers and acquisitions, legal affairs and corporate finance. Prior to joining Aurora, he served as Corporate Counsel at Science Applications International Corporation (SAIC), a multi-national technology development company. Prior to joining SAIC, he served as an attorney at Cooley Godward LLP and represented both privately-held and public companies in a wide range of transactions, including licensing, strategic alliances, mergers and acquisitions, public offerings and venture capital financings. Mr. Krueger received a BA in Economics from the University of California, San Diego and a JD and MBA from the University of Southern California.[top]
Kimberly J. Manhard
Senior Vice President, Regulatory Affairs and Development Operations
Ms. Manhard was appointed as our Senior Vice President of Regulatory Affairs and Development Operations in December, 2006. Prior to that, Ms. Manhard was President of her own consultancy since 2003, specializing in the development of small molecules intended for the treatment of antiviral, oncology, central nervous system (CNS), and gastrointestinal indications, and was responsible for filing five initial US INDs and multiple clinical trial applications in the European Union and Canada. Prior to starting her consultancy, Ms. Manhard was Vice President of Regulatory Affairs for Exelixis, Inc. Previously, she was Head of Regulatory Affairs for Agouron Global Commercial Operations (a Pfizer company) supporting marketed HIV products. She joined Agouron in 1996 as Director of Regulatory Affairs responsible for anticancer and antiviral products, including nelfinavir (Viracept®). Prior to Agouron, she was with Bristol-Myers Squibb for over five years in Regulatory Affairs and was responsible for investigational oncology compounds, including paclitaxel (Taxol®), and infectious disease compounds, including didanosine (Videx®) and stavudine (Zerit®). Ms Manhard began her industry career in Clinical Research with Eli Lilly and Company and G.H. Besselaar Associates (Covance). She earned a BS in Zoology and a BA in French from the University of Florida.[top]
Colin E. Rowlings, PhD
Senior Vice President, Pharmaceutical Sciences
Dr. Rowlings was appointed as our Senior Vice President of Pharmaceutical Sciences in April, 2007. Dr. Rowlings has been a consultant since 2005 and became President of his own consulting company in early 2007. Prior to this, Dr. Rowlings was Senior Vice President of Pharmaceutical Research and Development at Advancis Pharmaceutical Corp. Dr. Rowlings was at Advancis for four years and led the Pharmaceutical Research, Pharmaceutical Development Operations, Analytical Sciences, Project Management and Quality Assurance organizations. From 1997 to 2001, he was Director of Pharmaceutical Development at Agouron Pharmaceuticals, Inc. (now Pfizer, Inc.). Dr. Rowlings has also worked in Product Development at Rhone-Poulenc Rorer (now sanofi-aventis) and Eli Lilly and Company. Dr. Rowlings has a Bachelor of Pharmacy degree from the University of Queensland, Australia and a PhD in Pharmaceutics from the University of Iowa. [top]